The role of molecular pathology in non-small-cell lung carcinoma— now and in the future

Current Oncology

Volumn 19, Issue , 2012, Pages S24-S32

  Brandao, Guilherme D A ^a,b   Brega, E F ^a   Spatz, A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

biomarkers; EGFR; EML4 ALK; epidermal growth factor receptor; Non small cell lung carcinoma; nsclc; personalized medicine; tyrosine kinase inhibitors

Indexed keywords

EID: 84875074252     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1058     Document Type: Article

References (98)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
2. Reungwetwattana T, Weroha SJ, Molina JR. Oncogenic path-ways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (nsclc). Clin Lung Cancer 2011;:[Epub ahead of print].
3. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–91.
4. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cispla-tin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
5. Travis WD, Brambilla E, Van Schil P, et al. Paradigm shifts in lung cancer as defined in the new iaslc/ats/ers lung ad-enocarcinoma classification. Eur Respir J 2011;38:239–43.
6. Blons H, Côté JF, Le Corre D, et al. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloal-veolar differentiation. Am J Surg Pathol 2006;30:1309–15.
7. Shaw AT, Yeap BY, Mino–Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4–ALK. J Clin Oncol 2009;27:4247–53.
8. Finberg KE, Sequist LV, Joshi VA, et al. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 200;9:320–6.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor–related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.
10. Ladanyi M, Pao W. Lung adenocarcinoma: guiding egfr-targeted therapy and beyond. Mod Pathol 2008;21(suppl 2):S16–22.
11. Bell DW, Brannigan BW, Matsuo K, et al. Increased preva-lence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res 2008;14:4079–84.
12. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line egfr tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121–7.
13. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.
14. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med 2005;2:e73.
15. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling. Science 2007;316:1039–43.
16. Liu Y, Liu B, Li XY, et al. A comparison of arms and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res 2011;30:111.
17. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111–17.
18. Chowdhuri SR, Xi L, Pham TH, et al. EGFR and KRAS mutation analysis in cytologic samples of lung adenocarci-noma enabled by laser capture microdissection. Mod Pathol 2011;:[Epub ahead of print].
19. Kanaji N, Bandoh S, Ishii T, et al. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction. Mol Diagn Ther 2011;15:353–9.
20. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumour subtyping and feasibility of egfr and kras molecular testing. J Thorac Oncol 2011;6:451–8.
21. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4974–83.
22. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treat-ment. J Clin Oncol 2005;23:857–65.
23. Zhou C, Ni J, Zhao Y, Su B. Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-mgb probes. Cancer J 2006;12:33–9.
24. Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006;8:504–12.
25. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsu-domi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006;8:335–41.
26. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reac-tion–based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 2005;7:396–403.
27. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347–51.
28. Tanaka T, Nagai Y, Miyazawa H, et al. Reliability of the peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers. Cancer Sci 2007;98:246–52.
29. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915–21.
30. Cohen V, Agulnik JS, Jarry J, et al. Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer 2006;107:2858–65.
31. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852–5.
32. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006;12:43–8.
33. Hoshi K, Takakura H, Mitani Y, et al. Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process. Clin Cancer Res 2007;13:4974–83.
34. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.
35. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 1994;263:1281–4. [Erratum in: Science 1995;267:316–17]
36. Shiota M, Fujimoto J, Semba T, et al. Hyperphosphoryla-tion of a novel 80 kDa protein–tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994;9:1567–74.
37. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004;199:330–58.
38. Trinei M, Lanfrancone L, Campo E, et al. A new variant anaplastic lymphoma kinase (Alk)–fusion protein (atic-alk) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Res 2000;60:793–8.
39. Touriol C, Greenland C, Lamant L, et al. Further demonstra-tion of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000;95:3204–7.
40. Lamant L, Dastugue N, Pulford K, Delsol G, Mariamé B. A new fusion gene TPM3–ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 1999;93:3088–95.
41. Hernández L, Pinyol M, Hernández S, et al. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG–ALK translocations. Blood 1999;94:3265–8.
42. Lawrence B, Perez–Atayde A, Hibbard MK, et al. TPM3–ALK and TPM4–ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000;157:377–84.
43. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4–ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971–6.
44. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B–ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143–9.
45. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4–ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466–76.
46. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for Alk inhibitor treatment. Clin Cancer Res 2010;16:5581–90.
47. Inamura K, Takeuchi K, Togashi Y, et al. EML4–ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009;22:508–15.
48. Rodig SJ, Mino–Kenudson M, Dacic S, et al. Unique clini-copathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009;15:5216–23.
49. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4–ALK fusion gene and efficacy of an Alk kinase inhibitor in lung cancer. Clin Cancer Res 2008;14:4275–83.
50. UnitedStates, Department ofHealth andHumanServices, Food and Drug Administration (fda). Crizotinib [Web page]. Silver Spring, MD: fda; 2011. [Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm270058.htm; cited March 29, 2012]
51. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of Alk protein expression. J Thorac Oncol 2011;6:1359–66.
52. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 2009;40:1152–8.
53. Mino–Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immuno-histochemistry. Clin Cancer Res 2010;16:1561–71.
54. Martelli MP, Sozzi G, Hernandez L, et al. EML4–ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol 2009;174:661–70.
55. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–703.
56. Kranenburg O. The KRAS oncogene: past, present, and future. Biochim Biophys Acta 2005;1756:81–2.
57. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Are ras mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009;6:528–34.
58. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367–80.
59. Capella G, Cronauer–Mitra S, Pienado MA, Perucho M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ Health Perspect 1991;93:125–31.
60. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in devel-opmental disorders and cancer. Nat Rev Cancer 2007;7:295– 308. [Erratum in: Nat Rev Cancer 2007;7:563]
61. Roberts PJ, Der CJ. Targeting the Raf–Mek–Erk mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291–310.
62. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104:228–39.
63. Siegfried JM, Gillespie AT, Mera R, et al. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 1997;6:841–7.
64. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997–7000.
65. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is KRAS a use-ful marker in selecting patients for epidermal growth factor receptor–targeted therapy? J Clin Oncol 2010;28:4769–77.
66. Aviel–Ronen S, Blackhall FH, Shepherd FA, Tsao MS. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006;8:30–8.
67. Herbst RS, Kelly K, Chansky K, et al. Phase ii selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol 2010;28:4747–54.
68. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage i and ii non-small-cell lung cancer. J Clin Oncol 1999;17:668–75.
69. Li M, Liu L, Liu Z, et al. The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncol Rep 2009;22:1013–20.
70. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and dis-tinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14:5731–4.
71. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to egfr-tkis treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010;69:272–8.
72. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 2008;3:111–16.
73. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008;8:413–18.
74. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992–5.
75. Karapetis CS, Khambata–Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.
76. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
77. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561–5.
78. Mascaux C, Iannino N, Martin B, et al. The role of ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005;92:131–9.
79. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900–9.
80. Tsao MS, Aviel–Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007;25:5240–7.
81. Brugger W, Triller N, Blasinska–Morawiec M, et al. Prospec-tive molecular marker analyses of egfr and kras from a ran-domized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011;29:4113–20.
82. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the Raf–Erk signaling pathway by oncogenic mutations of B-raf. Cell 2004;116:855–67.
83. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54.
84. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574–9.
85. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF muta-tions. J Clin Oncol 2011;29:2046–51.
86. Kobayashi M, Sonobe M, Takahashi T, et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer. Anticancer Res 2011;31:4619–23.
87. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphoty-rosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190–203.
88. Ludovini V, Bianconi F, Pistola L, et al. Optimization of patient selection for egfr-tkis in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol 2012;:[Epub ahead of print].
89. Pellegrini C, Falleni M, Marchetti A, et al. her-2/neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription–pcr, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9:3645–52.
90. Jacobs CI. A review of the role of insulin-like growth factor 2 in malignancy and its potential as a modifier of radiation sensitivity. Clin Oncol (R Coll Radiol) 2008;20:345–52.
91. Guix M, Faber AC, Wang SE, et al. Acquired resistance to egfr tyrosine kinase inhibitors in cancer cells is mediated by loss of igf-binding proteins. J Clin Invest 2008;118:2609–19.
92. Ramalingam SS, Spigel DR, Chen D, et al. Randomized phase ii study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J Clin Oncol 2011;29:4574–80.
93. Weickhardt A, Doebele R, Oton A, et al. A phase i/ii study of erlotinib in combination with the anti-insulin-like growth fac-tor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. J Thorac Oncol 2012;7:419–26.
94. Cohen RB, Langer CJ, Simon GR, et al. A phase i/random-ized phase ii, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (nsclc). Cancer Chemother Pharmacol 2007;60:81–9.
95. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomark-ers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379–91.
96. Sang M, Lian Y, Zhou X, Shan B. mage-a family: attractive targets for cancer immunotherapy. Vaccine 2011;29:8496–500.
97. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in egfr in circulating lung-cancer cells. N Engl J Med 2008;359:366–77.
98. Parker–Pope T. Cancer funding: does it add up? [“Well” blog post] The New York Times March 6, 2008; 12:21 pm. [Available at: http://well.blogs.nytimes.com/2008/03/06/cancer-funding-does-it-add-up/; cited March 29,2012]